SEC Form 4 · accession 0001209191-18-045576

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP\Chief Commercial Officer

Period of report

Aug 2, 2018

Accepted (ET)

Aug 6, 2018 · 5:21 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Aug 2, 2018	M	2,125	$131.89	A	48,877	D
Common Stock	Aug 2, 2018	S	2,125	$179.00	D	46,752	D
Common Stock	Aug 2, 2018	M	2,155	$91.05	A	48,907	D
Common Stock	Aug 2, 2018	S	2,155	$174.59	D	46,752	D
Common Stock	Aug 3, 2018	M	4,250	$109.14	A	51,002	D
Common Stock	Aug 3, 2018	M	1,553	$86.52	A	52,555	D
Common Stock	Aug 3, 2018	S	5,803	$174.20	D	46,752	D
Common Stock	holding	—	—		—	140	I	401(k)

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F2	$131.89	Aug 2, 2018	M	2,125	D	—	Jul 20, 2025	Common Stock	2,125	8,500	D
Stock Option (Right to Buy)^F3	$91.05	Aug 2, 2018	M	2,155	D	—	Feb 1, 2026	Common Stock	2,155	12,931	D
Stock Option (Right to Buy)^F4	$109.14	Aug 3, 2018	M	4,250	D	—	Feb 2, 2025	Common Stock	4,250	8,500	D
Stock Option (Right to Buy)^F5	$86.52	Aug 3, 2018	M	1,553	D	—	Feb 2, 2027	Common Stock	1,553	15,533	D

F1Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.
F2The option vests in 16 quarterly installments from 7/21/2015.
F3The option vests in 16 quarterly installments from 2/2/2016.
F4The option vests in 16 quarterly installments from 2/3/2015.
F5The option vests in 16 quarterly installments from 2/3/2017.